Search results for "pharmacological"

showing 10 items of 131 documents

Long‐term molecular differences between resilient and susceptible mice after a single traumatic exposure

2022

Post-traumatic stress disorder (PTSD) is a heterogeneous disorder induced by trauma, resulting in severe long-term impairments of an individual's mental health. PTSD does not develop in every individual and, thus, some individuals are more resilient. However, the underlying molecular mechanisms are poorly understood. Here, we aimed to elucidate these processes.We used a single-trauma PTSD model in mice to induce long-term maladaptive behaviours and profiled the mice 4 weeks after trauma into resilient or susceptible individuals. The classification of phenotype was based on individual responses in different behavioural experiments. We analysed microbiome, circulating endocannabinoids, and lo…

Pharmacology610 MedizinBrainLipidomeBiologyPhenotypePharmacological treatmentStress Disorders Post-TraumaticTranscriptomeDisease Models AnimalMice610 Medical sciencesAnimalsMicrobiomebehavioural profiling ; microbiome ; resilience ; trauma ; endocannabinoids ; lipidomicsNeuroscienceOrganismHeterogeneous disorderPredictive biomarkerBritish Journal of Pharmacology
researchProduct

Pharmacological Properties of Polyphenols: Bioavailability, Mechanisms of Action, and Biological Effects in In Vitro Studies, Animal Models, and Huma…

2021

Este artículo se encuentra disponible en la siguiente URL: https://www.mdpi.com/2227-9059/9/8/1074 Este artículo de investigación pertenece al número especial "Oxidative Stress and Inflammation: From Mechanisms to Therapeutic Approaches 2.0". Drugs are bioactive compounds originally discovered from chemical structures present in both the plant and animal kingdoms. These have the ability to interact with molecules found in our body, blocking them, activating them, or increasing or decreasing their levels. Their actions have allowed us to cure diseases and improve our state of health, which has led us to increase the longevity of our species. Among the molecules with pharmacological activity …

Phenols - Physiological effect.Pharmacology.QH301-705.5Medicine (miscellaneous)Phenols - Properties.Farmacología.ReviewPharmacologyGeneral Biochemistry Genetics and Molecular BiologyDrugs - Bioavalability.drugsIn vivoconcomitanthumanBiology (General)Chemistrybiological effectsBiological activitypharmacologicalin vitroMedicamentos - Biodisponibilidad.In vitroBioavailabilityFenoles - Propiedades.mechanisms of actionpolyphenolin vivoPolyphenolFenoles - Efectos fisiológicos.bioavailabilityBiomedicines
researchProduct

Moral Attitudes Toward Pharmacological Cognitive Enhancement (PCE): Differences and Similarities Among Germans With and Without PCE Experience

2018

Pharmacological cognitive enhancement (PCE), the use of illicit and/or prescription drugs to increase cognitive performance, has spurred controversial discussion in bioethics. In a semi-structured interview study with 60 German university students and employees, differences and similarities in moral attitudes toward PCE among 30 experienced participants (EPs) vs. 30 inexperienced participants (IPs) were investigated. Substances EPs used most often are methylphenidate, amphetamines, tetrahydrocannabinol and modafinil. Both EPs and IPs addressed topics such as autonomous decision making or issues related to fairness such as equality in test evaluation and distortion of competition. While most…

Philosophy & psychologymedia_common.quotation_subjectfairness050105 experimental psychology03 medical and health sciencesIndividualism0302 clinical medicine0501 psychology and cognitive sciencesPharmacology (medical)Effects of sleep deprivation on cognitive performanceMedical prescriptionautonomymedia_commonPharmacologypharmacological cognitive enhancement05 social scienceslcsh:RM1-950StakeholderCognitionCommon senseBioethicsdistortion of competitionethicslcsh:Therapeutics. Pharmacologystimulantsddc:100Perspectiveinterview studyPsychologySocial psychology030217 neurology & neurosurgeryAutonomy
researchProduct

Moderate-Vigorous Physical Activity across Body Mass Index in Females : Moderating Effect of Endocannabinoids and Temperament

2014

Altres ajuts: This manuscript was supported by grants from Instituto Salud Carlos III (FIS PI11/210 and CIBERobn). Sarah Sauchelli is recipient of a pre-doctoral Grant (2013-17) by IDIBELL. Jose C. Fernández-García is recipient of a 'Rio Hortega' contract from 'Instituto de Salud Carlos III', Madrid, Spain (CM12/00059). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Endocannabinoids and temperament traits have been linked to both physical activity and body mass index (BMI) however no study has explored how these factors interact in females. The aims of this cross-sectional study were to 1) examine differences…

PhysiologyObesidad:Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings]Social SciencesDonesÍndice de masa corporalBlood plasmaBiochemistry:Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Size::Body Weight::Overweight::Obesity [Medical Subject Headings]Body Mass IndexMorbid obesityEndocrinologyFemalesMedicine and Health SciencesHomeostasisPsychologyPublic and Occupational HealthBody mass index (BMI)Big Five personality traitsmedia_commonMultidisciplinaryQRNeurochemistryMiddle AgedLipidsEating disordersEndocannabinoidesPhysiological ParametersHomeostatic MechanismsEating disordersMedicineHarm avoidanceObesitatFemaleBehavioral and Social Aspects of HealthBioelectrical impedance analysisResearch ArticlePersonality:Chemicals and Drugs::Lipids::Fatty Acids::Fatty Acids Unsaturated::Arachidonic Acids [Medical Subject Headings]Adultmedicine.medical_specialtyEsfuerzo físicoMujerSciencemedia_common.quotation_subjectObesitat mòrbidaExerciciMotor ActivityBiology:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Personality::Temperament [Medical Subject Headings]Internal medicinemedicine:Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Musculoskeletal Physiological Phenomena::Musculoskeletal Physiological Processes::Physical Exertion [Medical Subject Headings]HumansÁcidos araquidónicosWomenObesitySports and Exercise MedicineTemperamentTrastorns de la conducta alimentàriaExerciseMotivationBehavior:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Neurotransmitter Agents::Endocannabinoids [Medical Subject Headings]Human MovementPhysical activityTemperamentoBody WeightCognitive PsychologyNovelty seekingBiology and Life SciencesModerate-vigorous physical activity (MVPA)NeuroendocrinologyPlasma sanguinimedicine.diseaseObesityMorbid ObesityMetabolismEndocrinology:Check Tags::Female [Medical Subject Headings]Cognitive ScienceTemperamentEnergy MetabolismPhysiological ProcessesBody mass indexNeuroscienceEndocannabinoids
researchProduct

Pharmacological Induction of Redundant Genes for a Therapy of X-ALD

2003

X-linked adrenoleukodystrophy (X-ALD) is a recessive neurologic disease with an incidence among males of 1/17 000. Since the identification of the X-ALD gene (ABCD1) ten years ago (Mosser et al 1993), no satisfactory therapy has been available. A close homologue (ABCD2) was then cloned and presented as a putative modifier gene that could account for some of the extreme phenotypic variability of X-ALD (Lombard-Platet et al 1996). The inducibility of Abcd2 by the hypolipidemic drug fenofibrate in the liver of rodents (Albet et al 1997), correlated to a partial normalisation of the biochemical phenotype of X-ALD (Netik et al 1999), opened up the way of a pharmacological therapy of X-ALD. The b…

Pristanic acidcongenital hereditary and neonatal diseases and abnormalitiesFenofibrateendocrine system diseasesPharmacological therapybiologyPharmacologymedicine.diseasePhenylbutyrateBiochemical phenotypechemistry.chemical_compoundchemistrymedicineABCD2biology.proteinAdrenoleukodystrophyGenemedicine.drug
researchProduct

Pharmacological interventions for people with histrionic personality disorder

2011

Reason for withdrawal from publication Authors have made no progress with this protocol in over a year due to difficulties with identifying potentially suitable studies. The protocol has been withdrawn. To view the published versions of this article, please click the 'Other versions' tab.

Protocol (science)Pharmacological interventionsHistrionic personality disordermedicinePsychologymedicine.diseaseClinical psychology
researchProduct

Pharmacological interventions for people with narcissistic personality disorder

2011

Reason for withdrawal from publication Authors have made no progress with this protocol in over two years due to difficulties with identifying potentially suitable studies. The protocol has been withdrawn. To view the published versions of this article, please click the 'Other versions' tab.

Protocol (science)Pharmacological interventionsPsychotherapistbusiness.industryNarcissistic personality disorderMedicinebusinessmedicine.disease
researchProduct

Pharmacological interventions for schizoid personality disorder

2014

Reason for withdrawal from publication Authors have made no progress with this protocol in over three years due to difficulties with identifying potentially suitable studies. The protocol has been withdrawn. To view the published versions of this article, please click the 'Other versions' tab.

Protocol (science)PsychotherapistPharmacological interventionsSchizoid personality disordermedicinePsychologymedicine.diseasePersonality disordersClinical psychology
researchProduct

Pharmacological interventions for schizotypal personality disorder

2014

Reason for withdrawal from publication Authors have made no progress with this protocol in over a year due to difficulties with identifying potentially suitable studies. The protocol has been withdrawn. To view the published versions of this article, please click the 'Other versions' tab.

Protocol (science)medicine.medical_specialtyPsychotherapistPharmacological interventionsgenetic structuresbusiness.industryComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKSmedicineAlternative medicinemedicine.diseasebusinessSchizotypal personality disorderArticle
researchProduct

Pharmacological interventions for paranoid personality disorder

2014

Reason for withdrawal from publication Authors have made no progress with this protocol in over three years due to difficulties with identifying potentially suitable studies. The protocol has been withdrawn. To view the published versions of this article, please click the 'Other versions' tab.

Protocol (science)medicine.medical_specialtyPsychotherapistgenetic structuresbusiness.industryComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKSMEDLINEAlternative medicinemedicine.diseaseArticlePharmacological interventionsParanoid personality disordermedicinebusiness
researchProduct